Streetbeat News

Price Targets

NKE

Telsey Advisory Group has maintained an 'Outperform' rating on Nike but lowered its price target from $100 to $96.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 3:03 pm

LOW

Telsey Advisory Group has maintained a Market Perform rating on Lowe's Companies while raising the price target from $230 to $275.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 3:01 pm

FITB

In the past three months, 7 analysts have rated Fifth Third Bancorp (NASDAQ:FITB), with a mix of bullish and indifferent sentiments. The average 12-month price target has increased by 9.62% to $45.57. Analysts have raised their price targets, reflecting positive sentiment despite a recent revenue decline.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 3:00 pm

TFIN

Analysts have mixed ratings for Triumph Financial (NASDAQ:TFIN), with recent evaluations showing a slight upward trend in price targets. The average 12-month target is $69.6, up from $68.40. Analysts' ratings range from 'Neutral' to 'Underperform', reflecting varied expectations for the company's performance. Triumph Financial's revenue growth is notable, but challenges remain in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 3:00 pm

GOVX

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Geovax Labs (NASDAQ:GOVX) and maintained a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 2:56 pm

CLNN

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Clene (NASDAQ:CLNN) and maintained a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 2:54 pm

JOBY

HC Wainwright & Co. analyst Amit Dayal has reiterated a Buy rating for Joby Aviation and maintained a $9 price target.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 2:53 pm

SNOW

Rosenblatt analyst Blair Abernethy has reiterated a Buy rating for Snowflake (NYSE:SNOW) and maintained a price target of $180.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 2:51 pm

ESPR

HC Wainwright & Co. has reiterated its Buy rating for Esperion Therapeutics, maintaining a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 2:48 pm

LAZR

Rosenblatt analyst Kevin Cassidy has maintained a Neutral rating on Luminar Technologies (NASDAQ:LAZR) with a price target of $2.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 2:48 pm